Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

Share this content:
Allopurinol Dose Escalation for Gout Doesn't Improve Mortality
Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

THURSDAY, Sept. 20, 2018 (HealthDay News) -- Allopurinol dose escalation is not associated with reductions in mortality risk among patients with gout, according to a study published in the August issue of Arthritis & Rheumatology.

Brian W. Coburn, Ph.D., from the University of Nebraska Medical Center in Omaha, and colleagues assessed whether allopurinol dose escalation is associated with cause-specific mortality in patients with gout. The authors performed a 10-year observational, active-comparator study of U.S. veterans with gout who initiated treatment with allopurinol. The study included 6,428 dose escalators and 6,428 matched non-escalators.

The researchers found that there were 2,867 deaths during the observation period. There was an increase in all-cause mortality among dose escalators (hazard ratio, 1.08; 95 percent confidence interval, 1.01 to 1.17). Similar effect sizes were seen for incidence of cardiovascular-related deaths (hazard ratio, 1.08; 95 percent confidence interval, 0.97 to 1.21) and cancer-related deaths (hazard ratio, 1.06; 95 percent confidence interval, 0.88 to 1.27). At two years, 10 percent of dose escalators were receiving a final daily dose of >300 mg and 31 percent had achieved a serum urate goal of <6 mg/dL.

"A strategy of allopurinol dose escalation, which in current real-life practice is characterized by limited dose increases, is unlikely to improve the survival of patients with gout," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: First U.S. Case of Rat-Borne Andes Virus Diagnosed

CDC: First U.S. Case of Rat-Borne Andes Virus ...

New World hantavirus can present with symptoms similar to those of the flu

Variability in Geographic Availability of New Antibiotics

Variability in Geographic Availability of New Antibiotics

Greater geographic availability for antibiotics from and/or marketed by companies in U.S., Europe

CDC: Vaccination Rates More Than 95 Percent for Kindergartners

CDC: Vaccination Rates More Than 95 Percent for ...

Coverage could be even higher if schools followed up with under-vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »